Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Jazz Pharmaceuticals PLCJAZZ | $180.52 | Strong Buy | $235.00 | +30.18% | a day ago | |
Analyst RankingTop 12% #588 out of 5103 analysts Average Return+9.15% Win Rate63%66 out of 105 Risk vs RewardPoor Good Analyst ColorWells Fargo's Mohit Bansal raised their price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) by 38.2% from $170 to $235 on 2025/11/18. The analyst maintained their Strong Buy rating on the stock. Jazz Pharmaceuticals announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® in combination with chemotherapy on 2025/11/17. The readout on zanidatamab's effects on GEA (Gastroesophageal Adenocarcinoma) confirms its status as the gold standard treatment for this disease, Bansal told readers. The analyst estimates a roughly $3B unadjusted peak opportunity across two indications, noting that Zani's performance in GEA could also be a read-through to breast cancer. Data is anticipated in Q1 2026, possibly at ASCO GI, Bansal noted. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to ? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.